Welcome to our dedicated page for ARTELO BIOSCIENCES SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
Artelo Biosciences, Inc. (ARTL) filed a new Form D on 9 Jul 2025 that covers a $1.425 million private placement conducted under Regulation D Rule 506(b).
- Total offering & amount sold: $1,425,000; amount remaining: $0, indicating the raise is already fully subscribed.
- Date of first sale: 26 Jun 2025; the company does not expect the offering to last longer than one year.
- Securities offered: common equity, options/warrants, and the shares issuable upon exercise of those instruments.
- Investors: 8 accredited investors participated; no non-accredited investors and no minimum investment requirement were specified.
- Costs: No sales commissions or finders’ fees were paid, and none of the proceeds are earmarked for payments to directors, officers, or promoters.
- Industry & issuer details: Nevada-incorporated biotechnology company; revenue size not disclosed.
The notice signals completion of a small but cost-efficient capital raise that adds liquidity while increasing potential share count through equity-linked securities.
Artelo Biosciences (Nasdaq: ARTL) entered into a securities purchase agreement on 24-Jun-2025 for a private placement of 136,843 common shares at $5.82 plus warrants covering 783,249 shares.
Gross proceeds: $1.425 million today, up to $6.403 million if all warrants are exercised. Instruments include pre-funded warrants (93,180 shares, $0.001 strike) and 5-year warrants at $5.82 (460,046 shares) and $10.00 (230,023 shares), all subject to 4.99%-9.99% ownership caps.
- Unit price: $6.195 per share and three warrants.
- Closing expected 26-Jun-2025.
- Company will file resale registration within 15 days.
- $250,000 of net proceeds earmarked to purchase SOL cryptocurrency; remainder for working capital.
The sale is exempt under Rule 506 of Regulation D; investors are accredited.